Type: announcement

Abivax Secures $920 Million Funding to Prepare for Independent U.S. Launch of Bowel Disease Drug, CEO Marc de Garidel Tells CNBC

07/10/2026, 03:36 AM business announcement biotech
Abivax has successfully raised $920 million, enabling it to independently pursue the U.S. launch of its bowel disease drug, obefazimod, without relying on a potential acquisition. This funding positions the company to finance operations through 2029 and address recent investor concerns regarding the drug's safety and efficacy.